Literature DB >> 18201145

Androgen deprivation therapy for prostate cancer.

Eric A Singer1, Dragan J Golijanin, Hiroshi Miyamoto, Edward M Messing.   

Abstract

Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201145     DOI: 10.1517/14656566.9.2.211

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  29 in total

Review 1.  Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.

Authors:  Eric A Singer; Ramaprasad Srinivasan
Journal:  Urol Oncol       Date:  2011-10-19       Impact factor: 3.498

2.  Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.

Authors:  Siqi Xu; Xiaoyan Wu; Zhihua Tao; Hongsheng Li; Chenliang Fan; Songjin Chen; Jianwei Guo; Yao Ning; Xuqi Hu
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

Review 3.  Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.

Authors:  Lisa M Wu; Ali Amidi
Journal:  Curr Opin Support Palliat Care       Date:  2017-03       Impact factor: 2.302

4.  Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Authors:  Elisa Martín-Merino; Saga Johansson; Thomas Morris; Luis A García Rodríguez
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

5.  Redefining hormone resistance in prostate cancer.

Authors:  Christopher J Hoimes; W Kevin Kelly
Journal:  Ther Adv Med Oncol       Date:  2010-03-01       Impact factor: 8.168

6.  Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.

Authors:  Tong Sun; Gwo-Shu Mary Lee; Lillian Werner; Mark Pomerantz; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

7.  Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.

Authors:  Tong Sun; Lee Gwo-Shu Mary; William K Oh; Matthew L Freedman; Mark Pomerantz; Kenneth J Pienta; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

Review 8.  The complex interplay between cholesterol and prostate malignancy.

Authors:  Keith R Solomon; Michael R Freeman
Journal:  Urol Clin North Am       Date:  2011-06-22       Impact factor: 2.241

9.  Role of the androgen signaling axis in genitourinary malignancies.

Authors:  Brian M Shinder; Adam Shupe; Geun Taek Lee; Mark N Stein; Isaac Y Kim; Eric A Singer
Journal:  Transl Cancer Res       Date:  2018-08       Impact factor: 1.241

10.  Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.

Authors:  Young Kwang Chae; Han-Yao Huang; Paul Strickland; Sandra C Hoffman; Kathy Helzlsouer
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.